Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Switching From Salmeterol/Fluticasone to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic COPD Patients
Brief Summary: This study will investigate whether switching symptomatic COPD patients from a fixed-dose combination of salmeterol/fluticasone 50/500 µg b.i.d. to a fixed dose combination of QVA149 110/50 µg o.d. leads to improved lung function and airflow. It will also assess the effect on symptom burden, breathlessness, and use of rescue medication after this switch.


Options:
A: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Assigned to Arm(s): Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
B: Arm Label: Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium bromide/Vilanterol, Drug: Placebo ACCUHALER/DISKUS | Arm Label: Fluticasone propionate/Salmeterol + placebo NDPI; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/Salmeterol, Drug: Placebo NDPI | Intervention Type: DRUG; Name: Umeclidinium bromide/Vilanterol; Assigned to Arm(s): Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS | Intervention Type: DRUG; Name: Placebo ACCUHALER/DISKUS; Assigned to Arm(s): Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS | Intervention Type: DRUG; Name: Fluticasone propionate/Salmeterol; Assigned to Arm(s): Fluticasone propionate/Salmeterol + placebo NDPI | Intervention Type: DRUG; Name: Placebo NDPI; Assigned to Arm(s): Fluticasone propionate/Salmeterol + placebo NDPI
C: Arm Label: QVA149 110/50 micrograms; Type: EXPERIMENTAL; Interventions: Drug: QVA149 110/50 micrograms | Arm Label: salmeterol/fluticasone 50/500 micrograms; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol/fluticasone 50/500 microgrammes | Intervention Type: DRUG; Name: QVA149 110/50 micrograms; Assigned to Arm(s): QVA149 110/50 micrograms | Intervention Type: DRUG; Name: Salmeterol/fluticasone 50/500 microgrammes; Assigned to Arm(s): salmeterol/fluticasone 50/500 micrograms
D: Arm Label: BGF (PT010) MDI 320/14.4/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BGF MDI 320/14.4/9.6 μg | Arm Label: BGF (PT010) MDI 160/14.4/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BGF MDI 160/14.4/9.6 μg | Arm Label: BFF (PT009) MDI 320/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BFF MDI 320/9.6 μg | Arm Label: GFF (PT003) MDI 14.4/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: GFF MDI 14.4/9.6 μg | Intervention Type: DRUG; Name: BGF MDI 320/14.4/9.6 μg; Assigned to Arm(s): BGF (PT010) MDI 320/14.4/9.6 μg | Intervention Type: DRUG; Name: GFF MDI 14.4/9.6 μg; Assigned to Arm(s): GFF (PT003) MDI 14.4/9.6 μg | Intervention Type: DRUG; Name: BGF MDI 160/14.4/9.6 μg; Assigned to Arm(s): BGF (PT010) MDI 160/14.4/9.6 μg | Intervention Type: DRUG; Name: BFF MDI 320/9.6 μg; Assigned to Arm(s): BFF (PT009) MDI 320/9.6 μg

Answer: C